[Current treatment concepts for Peyronie's disease].
Aktuelle Behandlungskonzepte bei der Induratio penis plastica.
Corpus cavernosum
Deformity
Penile traction therapy
Penis
Tunica albuginea
Journal
Urologie (Heidelberg, Germany)
ISSN: 2731-7072
Titre abrégé: Urologie
Pays: Germany
ID NLM: 9918384886606676
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
20
09
2023
medline:
7
12
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
Plastic induration of the penis (PIP, Peyronie's disease) is an acquired and chronic disease of the penis, which is characterized by penile pain, distortion and deformation of the penis as well as the resulting impairments in sexual activity of the patient. The most probable causes are microtrauma and macrotrauma within the tunica albuginea of the corpora cavernosa, which due to an abnormal wound healing subsequently leads to the formation of fibrosis in this region. Various predisposing factors and also a genetic predisposition are discussed. The PIP occurs most frequently in the fifth to sixth decades of life. The prevalence is 0.3-20% depending on the investigated collective and the risk factors present. The PIP is subdivided into an acute inflammatory phase and a chronic postinflammatory phase. Various conservative and surgical treatment options include oral medication, penile traction therapy, intralesional injections and surgical procedures. Die Induratio penis plastica (IPP; Morbus Peyronie) ist eine erworbene und chronische Erkrankung des Penis, die durch penile Schmerzen, Verkrümmung und Deformität des Penis sowie daraus resultierende Beeinträchtigungen der sexuellen Aktivität der Patienten gekennzeichnet ist. Als wahrscheinlichste Ursachen gelten Makro- oder Mikrotraumata innerhalb der Tunica albuginea der Corpora cavernosa, welche in der Folge bei einer abnormalen Wundheilung zur Bildung einer Fibrose in diesem Bereich führen. Verschiedene prädisponierende Faktoren und auch eine genetische Veranlagung werden diskutiert. Die IPP tritt am häufigsten im 5. bis 6. Lebensjahrzehnt auf. Die Prävalenz liegt je nach untersuchtem Kollektiv und vorhandenen Risikofaktoren bei 0,3–20 %. Die IPP wird in eine akute inflammatorische Phase und eine chronische postinflammatorische Phase unterteilt. Unterschiedliche konservative und chirurgische Behandlungsoptionen umfassen orale Medikation, die penile Traktionstherapie, intraläsionale Injektionen und chirurgische Verfahren.
Autres résumés
Type: Publisher
(ger)
Die Induratio penis plastica (IPP; Morbus Peyronie) ist eine erworbene und chronische Erkrankung des Penis, die durch penile Schmerzen, Verkrümmung und Deformität des Penis sowie daraus resultierende Beeinträchtigungen der sexuellen Aktivität der Patienten gekennzeichnet ist. Als wahrscheinlichste Ursachen gelten Makro- oder Mikrotraumata innerhalb der Tunica albuginea der Corpora cavernosa, welche in der Folge bei einer abnormalen Wundheilung zur Bildung einer Fibrose in diesem Bereich führen. Verschiedene prädisponierende Faktoren und auch eine genetische Veranlagung werden diskutiert. Die IPP tritt am häufigsten im 5. bis 6. Lebensjahrzehnt auf. Die Prävalenz liegt je nach untersuchtem Kollektiv und vorhandenen Risikofaktoren bei 0,3–20 %. Die IPP wird in eine akute inflammatorische Phase und eine chronische postinflammatorische Phase unterteilt. Unterschiedliche konservative und chirurgische Behandlungsoptionen umfassen orale Medikation, die penile Traktionstherapie, intraläsionale Injektionen und chirurgische Verfahren.
Identifiants
pubmed: 37922029
doi: 10.1007/s00120-023-02213-2
pii: 10.1007/s00120-023-02213-2
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1332-1342Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Osmonov D, Ragheb A, Ward S, Blecher G, Falcone M, Soave A, Dahlem R, van Renterghem K, Christopher N, Hatzichristodoulou G, Preto M, Garaffa G, Albersen M, Bettocchi C, Corona G, Reisman Y (2022) ESSM position statement on surgical treatment of Peyronie’s disease. Sex Med 10:100459
pubmed: 34823053
doi: 10.1016/j.esxm.2021.100459
Soave A, König F, Dahlem RMR, Riechardt S, Fisch M, Briken P, Nieder TO (2021) Induratio penis plastica: Herausforderungen der somatischen Therapie und Unterstützungsmöglichkeiten durch Psychotherapie—Peyronie’s Disease: Challenges in Somatic Therapy and Support Opportunities via Psychotherapy. Z Sex Forsch 34(04):208–218
doi: 10.1055/a-1674-2041
Punjani N, Nascimento B, Salter C, Miranda E, Terrier J, Taniguchi H, Jenkins L, Mulhall JP (2021) Predictors of depression in men with Peyronie’s disease seeking evaluation. J Sex Med 18:783–788
pubmed: 33712403
pmcid: 9087901
doi: 10.1016/j.jsxm.2021.02.002
EAU (2022) Penile Curvature. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/penile-curvature . Zugegriffen: 4. März 2023
Di Maida F, Cito G, Lambertini L, Valastro F, Morelli G, Mari A, Carini M, Minervini A, Cocci A (2021) The natural history of Peyronie’s disease. World J Mens Health 39:399–405
pubmed: 32648381
doi: 10.5534/wjmh.200065
Ostrowski KA, Gannon JR, Walsh TJ (2016) A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol 8:61–70
pubmed: 27200305
pmcid: 4857830
Androutsos G (2002) François Gigot de La Peyronie(1678–1747), benefactor of surgery and supporter of the fusion of medicine and surgery, and the disease that bears his name. Prog Urol 12:527–533
pubmed: 12189772
Ziegelmann MJ, Bajic P, Levine LA (2020) Peyronie’s disease: Contemporary evaluation and management. Int J Urol 27:504–516
pubmed: 32253786
doi: 10.1111/iju.14230
Hughey JR, Paschou P, Drineas P, Mastropaolo D, Lotakis DM, Navas PA, Michalodimitrakis M, Stamatoyannopoulos JA, Stamatoyannopoulos G (2013) A European population in Minoan Bronze Age Crete. Nat Commun 4:1861
pubmed: 23673646
doi: 10.1038/ncomms2871
Laios K, Tsoucalas G, Karamanou M, Androutsos G (2013) Peyronie’s disease in Minoan art. J Sex Med 10:3144–3145
pubmed: 23578389
doi: 10.1111/jsm.12161
Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D (2016) The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS ONE 11:e150157
pubmed: 26907743
pmcid: 4764365
doi: 10.1371/journal.pone.0150157
La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F (2001) Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years. Eur Urol 40:525–530
pubmed: 11752860
doi: 10.1159/000049830
Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88:727–730
pubmed: 11890244
doi: 10.1046/j.1464-4096.2001.02436.x
Shiraishi K, Shimabukuro T, Matsuyama H (2012) The prevalence of Peyronie’s disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med 9:2716–2723
pubmed: 22897619
doi: 10.1111/j.1743-6109.2012.02868.x
Moghalu OI, Das R, Horns J, Campbell A, Hotaling JM, Pastuszak AW (2022) Regional variation in the incidence and prevalence of Peyronie’s disease in the United States—results from an encounters and claims database. Int J Impot Res 34:64–70
pubmed: 33024286
doi: 10.1038/s41443-020-00363-x
Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM (2006) Risk factors for Peyronie’s disease: a case-control study. BJU Int 97:570–574
pubmed: 16469028
doi: 10.1111/j.1464-410X.2006.05969.x
Jarow JP, Lowe FC (1997) Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 158:1388–1390
pubmed: 9302127
doi: 10.1016/S0022-5347(01)64222-8
Al-Thakafi S, Al-Hathal N (2016) Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol 5:280–289
pubmed: 27298774
pmcid: 4893516
doi: 10.21037/tau.2016.04.05
Gabrielsen JS (2020) Peyronie’s disease: is it genetic or not? Transl Androl Urol 9:S262–S268
pubmed: 32257867
pmcid: 7108984
doi: 10.21037/tau.2019.10.21
Meyers AL, Marquart MJ (2022) Plantar Fibromatosis. StatPearls Publishing, Treasure Island
Grunewald J, Eklund A, Olerup O (2004) Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 169:696–702
pubmed: 14656748
doi: 10.1164/rccm.200303-459OC
Nyberg LM Jr., Bias WB, Hochberg MC, Walsh PC (1982) Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 128:48–51
pubmed: 6980996
doi: 10.1016/S0022-5347(17)52751-2
Murphy-Ullrich JE, Suto MJ (2018) Thrombospondin‑1 regulation of latent TGF‑β activation: a therapeutic target for fibrotic disease. Matrix Biol 68–69:28–43
pubmed: 29288716
doi: 10.1016/j.matbio.2017.12.009
Bilgutay AN, Pastuszak AW (2016) Peyronie’s disease: what’s around the bend? Indian J Urol 32:6–14
pubmed: 26941488
pmcid: 4756553
doi: 10.4103/0970-1591.173107
Moreno SA, Morgentaler A (2009) Testosterone deficiency and Peyronie’s disease: pilot data suggesting a significant relationship. J Sex Med 6:1729–1735
pubmed: 19473459
doi: 10.1111/j.1743-6109.2009.01250.x
Kirby EW, Verges D, Matthews J, Carson CC, Coward RM (2015) Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie’s disease or erectile dysfunction and does not correlate with Peyronie’s disease severity. J Sex Med 12:690–696
pubmed: 25580982
doi: 10.1111/jsm.12805
Gelbard MK, Rosenbloom J (2021) Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie’s disease, Dupuytren disease and diabetes. Endocrinol Diabetes Metab 4:e195
pubmed: 33855203
doi: 10.1002/edm2.195
Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP (2010) Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med 7:1254–1261
pubmed: 20500447
doi: 10.1111/j.1743-6109.2009.01655.x
Milenkovic U, Ilg MM, Cellek S, Albersen M (2019) Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie’s disease. Sex Med Rev 7:679–689
pubmed: 30962046
doi: 10.1016/j.sxmr.2019.02.004
Patel DP, Christensen MB, Hotaling JM, Pastuszak AW (2020) A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol 38:253–261
pubmed: 31190155
doi: 10.1007/s00345-019-02815-6
El-Sakka AI, Salabas E, Dinçer M, Kadioglu A (2013) The pathophysiology of Peyronie’s disease. Arab J Urol 11:272–277
pubmed: 26558092
pmcid: 4442979
doi: 10.1016/j.aju.2013.06.006
Paulis G, De Giorgio G, Paulis L (2022) Role of oxidative stress in Peyronie’s disease: biochemical evidence and experiences of treatment with antioxidants. Int J Mol Sci 23(24):15969
pubmed: 36555611
pmcid: 9781573
doi: 10.3390/ijms232415969
Doersch KM, Barnett D, Chase A, Johnston D, Gabrielsen JS (2022) The contribution of the immune system to genitourinary fibrosis. Exp Biol Med (Maywood) 247:765–778
pubmed: 35531654
doi: 10.1177/15353702221090872
Manka MG, White LA, Yafi FA, Mulhall JP, Levine LA, Ziegelmann MJ (2021) Comparing and contrasting Peyronie’s disease guidelines: points of consensus and deviation. J Sex Med 18:363–375
pubmed: 33423972
pmcid: 8519165
doi: 10.1016/j.jsxm.2020.11.013
Traeger M, Leiber-Caspers C, Chierigo F, Cakir OO, Gratzke C, Schlager D (2023) Penile autophotography underestimates the degree of penile curvature in Peyronie’s disease. Eur Urol Focus 9:64–68
pubmed: 36335039
doi: 10.1016/j.euf.2022.10.009
Chung E, Deyoung L, Brock GB (2011) The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 8:1472–1477
pubmed: 21324095
doi: 10.1111/j.1743-6109.2011.02217.x
Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC, Nalbant I, Imamoglu MA (2014) Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci 183:449–453
pubmed: 24190613
doi: 10.1007/s11845-013-1036-5
Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, Trama F, Sciorio C, Sokolakis I, Creta M, Arcaniolo D (2022) Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis. Int J Impot Res. https://doi.org/10.1038/s41443-022-00651-8
doi: 10.1038/s41443-022-00651-8
pubmed: 36513814
Li EV, Esterquest R, Pham MN, Panken EJ, Amarasekera C, Siebert A, Bajic P, Levine LA (2021) Peyronie’s disease: pharmacological treatments and limitations. Expert Rev Clin Pharmacol 14:703–713
pubmed: 33719851
doi: 10.1080/17512433.2021.1903873
Weidner W, Hauck EW, Schnitker J (2005) Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 47:530–535 (discussion 535–536)
pubmed: 15774254
doi: 10.1016/j.eururo.2004.12.022
Yousif A, Natale C, Hellstrom WJG (2021) Conservative therapy for Peyronie’s disease: a contemporary review of the literature. Curr Urol Rep 22:6
pubmed: 33420664
doi: 10.1007/s11934-020-01024-8
Bole R, White L, Parikh N, Helo S, Kohler T, Ziegelmann M (2021) A modern review of penile traction monotherapy and combination therapy for the treatment of peyronie’s disease. Int J Impot Res 33:251–258
pubmed: 32152467
doi: 10.1038/s41443-020-0247-3
Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, Trost L (2019) Penile traction therapy and vacuum erection devices in Peyronie’s disease. Sex Med Rev 7:338–348
pubmed: 29631979
doi: 10.1016/j.sxmr.2018.02.005
MacDonald LP, Armstrong ML, Lehmann KJ, Acker MR, Langille GM (2020) Outcome analysis of patients with Peyronie’s disease who elect for vacuum erection device therapy. Can Urol Assoc J 14:E428–E431
pubmed: 32223874
pmcid: 7492030
Choi EJ, Xu P, El-Khatib FM, Yafi FA (2021) Intralesional injection therapy and atypical Peyronie’s disease: a systematic review. Sex Med Rev 9:434–444
pubmed: 32660728
doi: 10.1016/j.sxmr.2020.05.003
Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, Porst H, Levine L (2019) Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int 123:694–702
pubmed: 30365247
doi: 10.1111/bju.14602
Martínez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L, Sola I, Carballido J (2014) Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med 11:506–515
pubmed: 24261900
doi: 10.1111/jsm.12400
Bakr AM, El-Sakka AI (2021) Extracorporeal shockwave therapy in Peyronie’s disease: systematic review and meta-analysis. J Sex Med 18:1705–1714
pubmed: 34511369
doi: 10.1016/j.jsxm.2021.06.012
Bennett N, Yang KK (2015) Administration of Collagenase Clostridial Histolyticum (Cch) for Peyronie’s Disease. J Sex Med 12:2216–2220
pubmed: 26696220
doi: 10.1111/jsm.13063
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd (2013) Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 190:199–207
pubmed: 23376148
doi: 10.1016/j.juro.2013.01.087
Cocci A, Russo GI, Salamanca JIM, Ralph D, Palmieri A, Mondaini N (2020) The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European market. Eur Urol 77:660–661
pubmed: 31810821
doi: 10.1016/j.eururo.2019.11.019
Mefford AT, Raheem O, Yafi FA, Alzweri LM (2021) Peyronie’s disease—outcomes of collagenase clostridium histolyticum injection: A systematic review. Arab J Urol 19:363–369
pubmed: 34552787
pmcid: 8451611
doi: 10.1080/2090598X.2021.1957411
Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, Albersen M, Verze P (2019) Comparative effectiveness of Intralesional therapy for Peyronie’s disease in controlled clinical studies: a systematic review and network meta-analysis. J Sex Med 16:289–299
pubmed: 30692028
doi: 10.1016/j.jsxm.2018.12.011
Hayat S, Brunckhorst O, Alnajjar HM, Cakir OO, Muneer A, Ahmed K (2022) A systematic review of non-surgical management in Peyronie’s disease. Int J Impot Res. https://doi.org/10.1038/s41443-022-00633-w
doi: 10.1038/s41443-022-00633-w
pubmed: 36289392
pmcid: 10499596
García-Gómez B, González-Padilla DA, Alonso-Isa M, Medina-Polo J, Romero-Otero J (2020) Plication techniques in Peyronie’s disease: new developments. Int J Impot Res 32:30–36
pubmed: 31582822
doi: 10.1038/s41443-019-0204-1
Nesbit RM (1965) Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 93:230–232
pubmed: 14260875
doi: 10.1016/S0022-5347(17)63751-0
Pryor JP, Fitzpatrick JM (1979) A new approach to the correction of the penile deformity in Peyronie’s disease. J Urol 122:622–623
pubmed: 501814
doi: 10.1016/S0022-5347(17)56530-1
Yachia D (1990) Modified corporoplasty for the treatment of penile curvature. J Urol 143:80–82
pubmed: 2294269
doi: 10.1016/S0022-5347(17)39871-3
Gholami SS, Lue TF (2002) Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 167:2066–2069
pubmed: 11956440
doi: 10.1016/S0022-5347(05)65085-9
Garcia-Gomez B, Ralph D, Levine L, Moncada-Iribarren I, Djinovic R, Albersen M, Garcia-Cruz E, Romero-Otero J (2018) Grafts for Peyronie’s disease: a comprehensive review. Andrology 6:117–126
pubmed: 29266877
doi: 10.1111/andr.12421
Hatzichristodoulou G (2020) Novel approaches and new grafting materials in Peyronie’s disease reconstructive surgery. Int J Impot Res 32:37–42
pubmed: 31383990
doi: 10.1038/s41443-019-0179-y
Soave A, Laurich S, Dahlem R, Vetterlein MW, Engel O, Nieder T, Briken P, Rink M, Fisch M, Reiss P (2019) Negative self-perception and self-attitude of sexuality is a risk factor for patient dissatisfaction following penile surgery with small intestinal submucosa grafting for the treatment of severe Peyronie’s disease. J Clin Med 8(8):1121. https://doi.org/10.3390/jcm8081121
doi: 10.3390/jcm8081121
pubmed: 31357703
pmcid: 6722693
Sokolakis I, Pyrgidis N, Hatzichristodoulou G (2022) The use of collagen fleece (TachoSil) as grafting material in the surgical treatment of Peyronie’s disease. A comprehensive narrative review. Int J Impot Res 34:260–268
pubmed: 33452519
doi: 10.1038/s41443-020-00401-8
Lucas JW, Gross MS, Barlotta RM, Sudhakar A, Hoover CRV, Wilson SK, Simhan J (2020) Optimal modeling: an updated method for safely and effectively eliminating curvature during penile prosthesis implantation. Urology 146:133–139
pubmed: 32961224
doi: 10.1016/j.urology.2020.08.055
Wilson SK (2007) Surgical techniques: modeling technique for penile curvature. J Sex Med 4:231–234
pubmed: 17233788
doi: 10.1111/j.1743-6109.2007.00407.x
Sokolakis I, Pyrgidis N, Ziegelmann MJ, Mykoniatis I, Köhler TS, Hatzichristodoulou G (2022) Penile prosthesis implantation combined with grafting techniques in patients with Peyronie’s disease and erectile dysfunction: a systematic review. Sex Med Rev 10:451–459
pubmed: 34219005
doi: 10.1016/j.sxmr.2021.03.007
Colombo F, Franceschelli A, Gentile G, Droghetti M, Fiorillo A, Palmisano F (2021) The evolution in the surgical management of Peyronie’s disease. Urologia 88:79–89
pubmed: 33781136
doi: 10.1177/03915603211005326
Fernández-Pascual E, Franco QLM, Fraile Poblador A, Martínez-Ballesteros C, Martínez-Salamanca JI (2020) Complex Peyronie’s disease cases: surgery with or without penile prosthesis placement. Actas Urol Esp 44:351–356
pubmed: 32303370
doi: 10.1016/j.acuro.2020.01.008